Contact information
laurent.servais@paediatrics.ox.ac.uk
Fardowsi Kazi
fardowsi.kazi@paediatrics.ox.ac.uk
Laurent Servais
Professor of Paediatric Neuromuscular Diseases, Academic Director of the new Paediatric CRF
Biosketch
I am Professor of Paediatric Neuromuscular Diseases at the MDUK Oxford Neuromuscular Centre and Invited Professor of Child Neurology at Liège University.
After graduating from Louvain Medical School, Brussels, Belgium in 1999, I completed a PhD in Neuroscience (cerebellar electrophysiology in alert living mice) from Free University of Brussels, Belgium, followed by residencies in child neurology at the Free University of Brussels and Robert Debré Hospital, Paris. In 2008, I took a position in neuromuscular disease and clinical research at the Institute of Myology in Paris, where my interest and expertise in neuromuscular diseases flourished. I was subsequently appointed Head of Clinical Trials and Database Services. Most recently, I served as Head of the Institute of Myology’s I-Motion (Institute Of Muscle-Oriented Translational Innovation), and Head of the Neuromuscular Centre in Liège, Belgium. I have joined MD UK Oxford Neuromuscular Center and the University of Oxford in September 2019.
I have been involved as principal investigator in numerous clinical trials to test treatments for Duchenne muscular dystrophy and spinal muscular atrophy (SMA).
I am the leader of the newborn screening program for SMA in southern Belgium where we are conducting a medico-economic analysis of newborn screening. My main research expertise covers the development of innovative outcome measures, including connected devices for real-life patients’ evaluation.
Key publications
Risdiplam in Presymptomatic Spinal Muscular Atrophy.
Journal article
Finkel RS. et al, (2025), N Engl J Med, 393, 671 - 682
Recent publications
Corrigendum to "Learnings from a registry-based cohort study for spinal muscular atrophy disease" [Neuromuscular Disorders, Volume 59, February 2026, 106332].
Journal article
Jonker CJ. et al, (2026), Neuromuscul Disord
Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway.
Journal article
Finkel RS. et al, (2026), Expert Rev Neurother, 26, 211 - 225
Broad lessons from negative trials in rare diseases.
Journal article
Servais L. and Oskoui M., (2026), Lancet Neurol, 25, 215 - 217
A combined genomic and functional approach to One-Carbon Metabolism disorders in a population-based newborn screening
Preprint
Gernez E. et al, (2026)
2025 for neuromuscular diseases: a year of multiple advances.
Journal article
Servais L., (2026), Lancet Neurol, 25, 22 - 24